JP2012522802A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012522802A5 JP2012522802A5 JP2012503723A JP2012503723A JP2012522802A5 JP 2012522802 A5 JP2012522802 A5 JP 2012522802A5 JP 2012503723 A JP2012503723 A JP 2012503723A JP 2012503723 A JP2012503723 A JP 2012503723A JP 2012522802 A5 JP2012522802 A5 JP 2012522802A5
- Authority
- JP
- Japan
- Prior art keywords
- conjugate
- composition
- antigen
- hyperbranched polymer
- helper peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 24
- 239000000412 dendrimer Substances 0.000 claims 21
- 229920000736 dendritic polymer Polymers 0.000 claims 21
- 239000000427 antigen Substances 0.000 claims 19
- 102000036639 antigens Human genes 0.000 claims 19
- 108091007433 antigens Proteins 0.000 claims 19
- 229920000587 hyperbranched polymer Polymers 0.000 claims 19
- 101800000324 Immunoglobulin A1 protease translocator Proteins 0.000 claims 15
- 108020004707 nucleic acids Proteins 0.000 claims 12
- 102000039446 nucleic acids Human genes 0.000 claims 12
- 150000007523 nucleic acids Chemical class 0.000 claims 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims 10
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 9
- 230000028993 immune response Effects 0.000 claims 9
- 241000124008 Mammalia Species 0.000 claims 7
- 210000004027 cell Anatomy 0.000 claims 7
- 230000001939 inductive effect Effects 0.000 claims 6
- 102000043131 MHC class II family Human genes 0.000 claims 5
- 108091054438 MHC class II family Proteins 0.000 claims 5
- 241001465754 Metazoa Species 0.000 claims 5
- 238000000338 in vitro Methods 0.000 claims 5
- 229920001184 polypeptide Polymers 0.000 claims 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims 5
- 210000004881 tumor cell Anatomy 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 108020004459 Small interfering RNA Proteins 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 230000006907 apoptotic process Effects 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 230000002458 infectious effect Effects 0.000 claims 2
- 206010022000 influenza Diseases 0.000 claims 2
- 108091070501 miRNA Proteins 0.000 claims 2
- 239000002679 microRNA Substances 0.000 claims 2
- SENLDUJVTGGYIH-UHFFFAOYSA-N n-(2-aminoethyl)-3-[[3-(2-aminoethylamino)-3-oxopropyl]-[2-[bis[3-(2-aminoethylamino)-3-oxopropyl]amino]ethyl]amino]propanamide Chemical group NCCNC(=O)CCN(CCC(=O)NCCN)CCN(CCC(=O)NCCN)CCC(=O)NCCN SENLDUJVTGGYIH-UHFFFAOYSA-N 0.000 claims 2
- 244000052769 pathogen Species 0.000 claims 2
- 230000001717 pathogenic effect Effects 0.000 claims 2
- 229920000962 poly(amidoamine) Polymers 0.000 claims 2
- 229920000642 polymer Polymers 0.000 claims 2
- 239000007762 w/o emulsion Substances 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16573209P | 2009-04-01 | 2009-04-01 | |
| US61/165,732 | 2009-04-01 | ||
| PCT/US2010/029694 WO2010115046A2 (en) | 2009-04-01 | 2010-04-01 | Vaccine compositions and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014243829A Division JP2015096520A (ja) | 2009-04-01 | 2014-12-02 | ワクチン組成物及びその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012522802A JP2012522802A (ja) | 2012-09-27 |
| JP2012522802A5 true JP2012522802A5 (OSRAM) | 2013-05-23 |
| JP5661735B2 JP5661735B2 (ja) | 2015-01-28 |
Family
ID=42828943
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012503723A Expired - Fee Related JP5661735B2 (ja) | 2009-04-01 | 2010-04-01 | ワクチン組成物及びその使用方法 |
| JP2014243829A Pending JP2015096520A (ja) | 2009-04-01 | 2014-12-02 | ワクチン組成物及びその使用方法 |
| JP2016105809A Expired - Fee Related JP6139000B2 (ja) | 2009-04-01 | 2016-05-27 | ワクチン組成物及びその使用方法 |
| JP2017086900A Expired - Fee Related JP6321261B2 (ja) | 2009-04-01 | 2017-04-26 | ワクチン組成物及びその使用方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014243829A Pending JP2015096520A (ja) | 2009-04-01 | 2014-12-02 | ワクチン組成物及びその使用方法 |
| JP2016105809A Expired - Fee Related JP6139000B2 (ja) | 2009-04-01 | 2016-05-27 | ワクチン組成物及びその使用方法 |
| JP2017086900A Expired - Fee Related JP6321261B2 (ja) | 2009-04-01 | 2017-04-26 | ワクチン組成物及びその使用方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US9764012B2 (OSRAM) |
| EP (1) | EP2413964B1 (OSRAM) |
| JP (4) | JP5661735B2 (OSRAM) |
| CN (2) | CN107050440B (OSRAM) |
| AU (1) | AU2010232512B2 (OSRAM) |
| BR (1) | BRPI1016133A2 (OSRAM) |
| CA (1) | CA2756996C (OSRAM) |
| RU (2) | RU2016137258A (OSRAM) |
| WO (1) | WO2010115046A2 (OSRAM) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2476435T (pt) | 2006-08-11 | 2018-03-05 | Life Sciences Res Partners Vzw | Péptidos imunogénicos e a sua utilização em distúrbios imunitários |
| US8999346B2 (en) | 2008-02-14 | 2015-04-07 | Life Sciences Research Partners Vzw | Immunogenic control of tumours and tumour cells |
| CA2756996C (en) | 2009-04-01 | 2018-12-11 | University Of Miami | Vaccine compositions and methods of use thereof |
| WO2010135394A1 (en) * | 2009-05-19 | 2010-11-25 | University Of Miami | Compositions, kits and methods for in vitro antigen presentation, assessing vaccine efficacy, and assessing immunotoxicity of biologics and drugs |
| WO2010138193A2 (en) | 2009-05-27 | 2010-12-02 | Selecta Biosciences, Inc. | Targeted synthetic nanocarriers with ph sensitive release of immunomodulatory agents |
| US20110293700A1 (en) | 2010-05-26 | 2011-12-01 | Selecta Biosciences, Inc. | Nanocarrier compositions with uncoupled adjuvant |
| EP2640190A4 (en) | 2010-11-05 | 2016-05-11 | Selecta Biosciences Inc | MODIFIED NICOTINIC COMPOUNDS AND ASSOCIATED METHODS |
| CN109172819A (zh) | 2011-07-29 | 2019-01-11 | 西莱克塔生物科技公司 | 产生体液和细胞毒性t淋巴细胞（ctl）免疫应答的合成纳米载体 |
| KR20140084020A (ko) * | 2011-09-07 | 2014-07-04 | 미다테크 리미티드 | 나노입자 종양 백신 |
| WO2013034726A1 (en) * | 2011-09-07 | 2013-03-14 | Midatech Limited | Nanoparticle-peptide compositions |
| GB201201511D0 (en) * | 2012-01-30 | 2012-03-14 | Univ Leuven Kath | Modified epitopes for boosting CD4+ T-cell responses |
| WO2014120804A1 (en) * | 2013-01-30 | 2014-08-07 | University Of Miami | Enteric coated nanoparticles for oral vaccine and drug delivery and methods of production and use thereof |
| CA2840978A1 (en) * | 2013-02-05 | 2014-08-05 | Nitto Denko Corporation | Vaccine composition for mucosal administration |
| KR20140100415A (ko) * | 2013-02-05 | 2014-08-14 | 닛토덴코 가부시키가이샤 | 경피 투여용 백신 조성물 |
| WO2014168724A1 (en) * | 2013-03-15 | 2014-10-16 | University Of Miami | Immune-potentiating drug nanocarriers |
| GB201309469D0 (en) | 2013-05-28 | 2013-07-10 | Imcyse Sa | Detection of CD4+ T lymphocytes |
| ES2891081T3 (es) * | 2013-08-27 | 2022-01-26 | Deutsches Krebsforsch | Modificadores de la respuesta de células T citotóxicas |
| CN105792842B (zh) * | 2013-10-11 | 2020-06-02 | 美利坚合众国, 由健康及人类服务部部长代表 | 埃巴病毒疫苗 |
| WO2015116568A2 (en) * | 2014-01-28 | 2015-08-06 | University Of Miami | Muscle cell-targeting nanoparticles for vaccination and nucleic acid delivery, and methods of production and use thereof |
| GB201418433D0 (en) | 2014-10-17 | 2014-12-03 | Imcyse Sa | Novel immunogenic peptides |
| US10729791B2 (en) | 2015-05-18 | 2020-08-04 | Imcyse Sa | Animal models for evaluating pharmaceutical compounds |
| US11364292B2 (en) | 2015-07-21 | 2022-06-21 | Modernatx, Inc. | CHIKV RNA vaccines |
| EP4218805A1 (en) | 2015-07-21 | 2023-08-02 | ModernaTX, Inc. | Infectious disease vaccines |
| CA2999916C (en) * | 2015-09-23 | 2021-07-20 | Massachusetts Institute Of Technology | Compositions and methods for modified dendrimer nanoparticle vaccine delivery |
| WO2017070624A1 (en) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Tropical disease vaccines |
| AU2016342376A1 (en) | 2015-10-22 | 2018-06-07 | Modernatx, Inc. | Sexually transmitted disease vaccines |
| CN117731769A (zh) | 2015-10-22 | 2024-03-22 | 摩登纳特斯有限公司 | 用于水痘带状疱疹病毒(vzv)的核酸疫苗 |
| US20190184013A1 (en) * | 2016-05-23 | 2019-06-20 | University Of Miami | Compositions for selective humoral responses and methods of use thereof |
| WO2017216768A1 (en) | 2016-06-16 | 2017-12-21 | Association For The Advancement Of Tissue Engineering And Cell Based Technologies And Therapies - A4Tec | Dendrimer-derived artificial antigen, methods and uses thereof |
| US10925958B2 (en) | 2016-11-11 | 2021-02-23 | Modernatx, Inc. | Influenza vaccine |
| MA50335A (fr) | 2016-12-08 | 2020-08-19 | Modernatx Inc | Vaccins à acide nucléique contre des virus respiratoires |
| MA47515A (fr) | 2017-02-16 | 2019-12-25 | Modernatx Inc | Compositions immunogènes très puissantes |
| WO2018170270A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Varicella zoster virus (vzv) vaccine |
| US11752206B2 (en) | 2017-03-15 | 2023-09-12 | Modernatx, Inc. | Herpes simplex virus vaccine |
| US11576961B2 (en) | 2017-03-15 | 2023-02-14 | Modernatx, Inc. | Broad spectrum influenza virus vaccine |
| EP3595713A4 (en) | 2017-03-15 | 2021-01-13 | ModernaTX, Inc. | Respiratory syncytial virus vaccine |
| WO2018237010A2 (en) * | 2017-06-20 | 2018-12-27 | The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Vaccine compositions and methods of using the same |
| US10988754B2 (en) * | 2017-07-04 | 2021-04-27 | Cure Vac AG | Nucleic acid molecules |
| MA50253A (fr) | 2017-09-14 | 2020-07-22 | Modernatx Inc | Vaccins à arn contre le virus zika |
| ES3021410T3 (en) | 2018-01-28 | 2025-05-26 | Enable Biosciences Inc | Reagents and methods for blocking non-specific interactions with nucleic acids |
| US11911453B2 (en) | 2018-01-29 | 2024-02-27 | Modernatx, Inc. | RSV RNA vaccines |
| TW202028222A (zh) | 2018-11-14 | 2020-08-01 | 美商Ionis製藥公司 | Foxp3表現之調節劑 |
| US11351242B1 (en) | 2019-02-12 | 2022-06-07 | Modernatx, Inc. | HMPV/hPIV3 mRNA vaccine composition |
| MA55321A (fr) | 2019-03-15 | 2022-01-19 | Modernatx Inc | Vaccins à base d'arn contre le vih |
| CN110448695B (zh) * | 2019-08-23 | 2021-07-27 | 中山大学肿瘤防治中心 | 一种mRNA疫苗递送载体及其制备方法 |
| CN113173985A (zh) * | 2021-03-24 | 2021-07-27 | 深圳市新靶向生物科技有限公司 | 一种与结直肠癌驱动基因突变相关的抗原肽及其应用 |
| CN120209073B (zh) * | 2025-05-28 | 2025-09-23 | 北京立康生命科技有限公司 | 一种有利于抗原呈递的间隔肽 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3023A (en) * | 1843-03-30 | peters | ||
| US8003A (en) * | 1851-03-25 | Improvement in scythe-tastenings | ||
| US20050169900A1 (en) | 1993-02-17 | 2005-08-04 | Sloan Kettering Institute For Cancer Research | Allogeneic vaccine and methods to synthesize same |
| US6864060B1 (en) * | 1993-03-31 | 2005-03-08 | Cadus Technologies, Inc. | Yeast cells expressing modified G proteins and methods of use therefor |
| EP0735893B1 (en) | 1993-09-14 | 2008-11-26 | Pharmexa Inc. | Pan dr-binding peptides for enhancement of the immune response |
| CA2184132C (en) | 1995-09-21 | 2011-03-15 | Kristina J. Hennessy | An adjuvanted vaccine which is substantially free of non-host albumin |
| US6204250B1 (en) * | 1996-11-22 | 2001-03-20 | The Mount Sinai Medical Center Of The City Of New York | Immunization of infants |
| EP0969873B1 (en) | 1997-03-27 | 2006-06-07 | Institut Pasteur | Multiple antigen glycopeptide carbohydrate, vaccine comprising the same and use thereof |
| AU9031798A (en) * | 1997-08-22 | 1999-03-16 | Richard C. Morlock | Sensor housing for uv curing chamber |
| DE69918146T2 (de) | 1998-10-05 | 2005-07-07 | Pharmexa A/S | Verfahren zur therapeutischen impfung |
| US7807377B2 (en) | 1998-10-20 | 2010-10-05 | Salvatore Albani | Method of isolating antigen-specific T cells employing artificial antigen presenting cells |
| US20040241842A1 (en) | 1999-04-15 | 2004-12-02 | Monash University | Stimulation of thymus for vaccination development |
| US6632435B1 (en) | 1999-10-20 | 2003-10-14 | City Of Hope | CTL epitope analogs |
| JP2003516344A (ja) * | 1999-12-13 | 2003-05-13 | エピミューン， インコーポレイテッド | Ｈｌａクラスｉａ２腫瘍関連抗原ペプチドおよびワクチン組成物 |
| AUPR011700A0 (en) | 2000-09-14 | 2000-10-05 | Austin Research Institute, The | Composition comprising immunogenic virus sized particles (VSP) |
| CA2349506C (en) | 2001-06-14 | 2009-12-08 | Duke University | A method for selective expression of therapeutic genes by hyperthermia |
| EP1473564A4 (en) | 2001-09-18 | 2008-12-10 | Greenpeptide Co Ltd | METHOD FOR DETECTING CELL IMMUNITY AND ITS APPLICATION TO MEDICAMENTS |
| KR20050044857A (ko) | 2001-11-16 | 2005-05-13 | 파멕사 에이/에스 | 무차별 ｔ 세포 에피토프 삽입물을 갖는 멀티머 단백질의면역원성 모방체 |
| US7261875B2 (en) * | 2001-12-21 | 2007-08-28 | Board Of Regents, The University Of Texas System | Dendritic poly (amino acid) carriers and methods of use |
| AU2003208314A1 (en) | 2002-03-11 | 2003-09-22 | Pharmexa A/S | Novel application of vaccination against tnf-alpha |
| US20080268457A1 (en) | 2002-11-14 | 2008-10-30 | Dharmacon, Inc. | siRNA targeting forkhead box P3 (FOXP3) |
| CN1809379A (zh) | 2003-04-18 | 2006-07-26 | 诺伍德免疫学有限公司 | 先于胸腺再活化的疾病预防和疫苗接种 |
| CN101506266A (zh) | 2005-02-01 | 2009-08-12 | 梅迪沃什有限公司 | 疫苗输送组合物及使用方法 |
| US7358231B1 (en) | 2005-12-01 | 2008-04-15 | Applera Corporation | Pancreatic cancer secreted targets and uses thereof |
| CA2638906A1 (en) | 2006-01-26 | 2007-08-16 | University Of Massachusetts | Rna interference agents for therapeutic use |
| US8954355B2 (en) * | 2006-01-26 | 2015-02-10 | Psi Systems, Inc. | Integrated postage and shipping label system |
| CA2657849A1 (en) * | 2006-05-18 | 2008-05-08 | Pharmexa Inc. | Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions |
| JP5700934B2 (ja) | 2007-03-16 | 2015-04-15 | セルスティス リミテッド | 細胞性免疫反応アッセイおよびそのためのキット |
| WO2008151389A1 (en) * | 2007-06-15 | 2008-12-18 | Macfarlane Burnet Institute For Medical Research And Public Health Limited | Chemically modified macromolecules |
| MX2010001194A (es) * | 2007-07-31 | 2010-07-30 | Univ Louisiana State | Conjugado de polipeptido-acido nucleico para inmunoprofilaxis o inmunoterapia para desordenes neoplasicos o infecciones. |
| CA2756996C (en) | 2009-04-01 | 2018-12-11 | University Of Miami | Vaccine compositions and methods of use thereof |
-
2010
- 2010-04-01 CA CA2756996A patent/CA2756996C/en not_active Expired - Fee Related
- 2010-04-01 CN CN201710198161.XA patent/CN107050440B/zh not_active Expired - Fee Related
- 2010-04-01 EP EP10759434.3A patent/EP2413964B1/en active Active
- 2010-04-01 JP JP2012503723A patent/JP5661735B2/ja not_active Expired - Fee Related
- 2010-04-01 RU RU2016137258A patent/RU2016137258A/ru not_active Application Discontinuation
- 2010-04-01 WO PCT/US2010/029694 patent/WO2010115046A2/en not_active Ceased
- 2010-04-01 RU RU2011144089/15A patent/RU2600798C2/ru not_active IP Right Cessation
- 2010-04-01 US US13/262,285 patent/US9764012B2/en not_active Expired - Fee Related
- 2010-04-01 CN CN2010800250670A patent/CN102448491A/zh active Pending
- 2010-04-01 BR BRPI1016133A patent/BRPI1016133A2/pt not_active Application Discontinuation
- 2010-04-01 AU AU2010232512A patent/AU2010232512B2/en not_active Ceased
-
2014
- 2014-12-02 JP JP2014243829A patent/JP2015096520A/ja active Pending
-
2016
- 2016-05-27 JP JP2016105809A patent/JP6139000B2/ja not_active Expired - Fee Related
-
2017
- 2017-04-26 JP JP2017086900A patent/JP6321261B2/ja not_active Expired - Fee Related
- 2017-09-15 US US15/705,520 patent/US20180099032A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012522802A5 (OSRAM) | ||
| Liu et al. | Arginine-terminated generation 4 PAMAM dendrimer as an effective nanovector for functional siRNA delivery in vitro and in vivo | |
| El-Sayed et al. | Delivery of macromolecules using arginine-rich cell-penetrating peptides: ways to overcome endosomal entrapment | |
| JP6321261B2 (ja) | ワクチン組成物及びその使用方法 | |
| Hassan et al. | Dual stimulation of antigen presenting cells using carbon nanotube-based vaccine delivery system for cancer immunotherapy | |
| Li et al. | Rational design of polymeric hybrid micelles to overcome lymphatic and intracellular delivery barriers in cancer immunotherapy | |
| Kim et al. | Nanosac, a noncationic and soft polyphenol nanocapsule, enables systemic delivery of siRNA to solid tumors | |
| ES2754239T3 (es) | Combinación de vacunación y agonistas de OX40 | |
| Deng et al. | Self-assembled cationic micelles based on PEG-PLL-PLLeu hybrid polypeptides as highly effective gene vectors | |
| Tanaka et al. | Cytoplasm-responsive nanocarriers conjugated with a functional cell-penetrating peptide for systemic siRNA delivery | |
| Tambe et al. | Triptorelin tethered multifunctional PAMAM-histidine-PEG nanoconstructs enable specific targeting and efficient gene silencing in LHRH overexpressing cancer cells | |
| JP2012521201A5 (OSRAM) | ||
| JP2015529678A5 (OSRAM) | ||
| Avila et al. | Gene delivery and immunomodulatory effects of plasmid DNA associated with Branched Amphiphilic Peptide Capsules | |
| EP3630807A1 (en) | Pd-1 and ctla-4 dual inhibitor peptides | |
| JP2015533376A5 (OSRAM) | ||
| JP2014502961A5 (OSRAM) | ||
| JP2022517236A (ja) | 自己組織化ペプチドナノ粒子およびその使用 | |
| Hong et al. | An mRNA vaccine against SARS-CoV-2: Lyophilized, liposome-based vaccine candidate EG-COVID induces high levels of virus neutralizing antibodies | |
| Kang et al. | Self-assembled nanoparticles based on DNA origami and a nitrated T helper cell epitope as a platform for the development of personalized cancer vaccines | |
| Xiao et al. | Immunoregulatory nanomedicine for respiratory infections | |
| He et al. | A novel pan-epitope based nanovaccine self-assembled with CpG enhances immune responses against flavivirus | |
| Wang et al. | Spatiotemporal Nano‐Regulator Unleashes Anti‐Tumor Immunity by Overcoming Dendritic Cell Tolerance and T Cell Exhaustion in Tumor‐Draining Lymph Nodes | |
| US20230293448A1 (en) | Nanoparticle immunogenic compositions and vaccination methods | |
| Zuber et al. | Synthetic viruslike particles for targeted gene delivery to αvβ3 integrin-presenting endothelial cells |